Curanex’s Phyto-N Cuts Amylase 53% and Lipase 83% in Patient Study
Curanex’s Phyto-N improved serum amylase from 191 to 90, lipase from 298 to 52 and triglycerides from 164 to 77 in a pancreatic neuroendocrine tumor patient, enabling him to work and resume daily life. The company plans Phyto-N development for cancer cachexia care, addressing a market with no approved therapies.
1. Patient Case Study
A senior dosimetrist with a pancreatic neuroendocrine tumor experiencing severe cachexia received Phyto-N treatment and reported marked symptomatic relief within one month, including resolution of abdominal pain, normalized complexion and reduced urinary frequency, allowing him to maintain work and daily activities.
2. Clinical Biomarker Improvements
Follow-up lab tests three months after treatment showed serum amylase drop from 191 to 90, lipase from 298 to 52 and triglycerides from 164 to 77, while HDL and LDL levels normalized and MRI scans indicated stable disease without progression.
3. Strategic Focus on Cachexia Supportive Care
Curanex is expanding its development strategy to include cancer cachexia, a syndrome affecting up to 80% of advanced cancer patients with no approved therapies, positioning Phyto-N as a potential supportive-care asset within its pipeline alongside planned ulcerative colitis IND preparations.